DiaMedica Therapeutics (NASDAQ:DMAC) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of DiaMedica Therapeutics (NASDAQ:DMAC) from a hold rating to a sell rating in a research report released on Saturday morning.

Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald initiated coverage on shares of DiaMedica Therapeutics in a research note on Friday. They issued an “overweight” rating for the company. Lake Street Capital upped their price target on DiaMedica Therapeutics from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, July 18th. Cowen started coverage on DiaMedica Therapeutics in a research report on Thursday, October 30th. They set a “buy” rating on the stock. Craig Hallum boosted their price objective on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Friday, July 18th. Finally, TD Cowen started coverage on DiaMedica Therapeutics in a research note on Thursday, October 30th. They issued a “buy” rating for the company. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Stock Performance

Shares of DMAC traded up $0.51 during mid-day trading on Friday, hitting $5.93. 637,150 shares of the company’s stock were exchanged, compared to its average volume of 231,004. The stock’s 50-day moving average is $6.77 and its 200-day moving average is $5.25. The company has a market cap of $308.82 million, a price-to-earnings ratio of -8.59 and a beta of 1.42. DiaMedica Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $7.49.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). As a group, equities research analysts anticipate that DiaMedica Therapeutics will post -0.59 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Jan Stahlberg bought 338,265 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average price of $6.00 per share, for a total transaction of $2,029,590.00. Following the transaction, the insider directly owned 7,654,045 shares of the company’s stock, valued at $45,924,270. This represents a 4.62% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have acquired 627,752 shares of company stock worth $3,752,239. Corporate insiders own 7.30% of the company’s stock.

Hedge Funds Weigh In On DiaMedica Therapeutics

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in shares of DiaMedica Therapeutics by 99.6% during the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after purchasing an additional 314,407 shares during the last quarter. Paragon Associates & Paragon Associates II Joint Venture grew its position in shares of DiaMedica Therapeutics by 34.6% in the 3rd quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after acquiring an additional 225,000 shares during the period. Royal Bank of Canada grew its position in DiaMedica Therapeutics by 46,879.1% during the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after acquiring an additional 154,701 shares during the last quarter. Corient IA LLC bought a new stake in DiaMedica Therapeutics during the 3rd quarter worth approximately $910,000. Finally, Osaic Holdings Inc. increased its position in shares of DiaMedica Therapeutics by 374.7% during the 2nd quarter. Osaic Holdings Inc. now owns 144,290 shares of the company’s stock valued at $563,000 after purchasing an additional 113,893 shares during the last quarter. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.